Tranylcypromine-Trifluoperazine Combination in the Treatment of Schizophrenia
Abstract
Ninety-six schizophrenic patients participated in a double-blind, crossover study of the efficacy of trifluoperazine and tranylcypromine therapy alone and in combination. Pseudoneurotic patients had a statistically significant response to tranylcypromine; paranoid (chronic undifferentiated) patients responded best to the combination therapy. The authors urge the use of computer-derived profiles of patients' symptom clusters rather than their diagnoses to ensure selection of the optimum drug therapy.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
